139 related articles for article (PubMed ID: 14990394)
1. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk.
Ohkubo T; Chapman N; Neal B; Woodward M; Omae T; Chalmers J;
Am J Respir Crit Care Med; 2004 May; 169(9):1041-5. PubMed ID: 14990394
[TBL] [Abstract][Full Text] [Related]
2. Reduction of pneumonia risk by an angiotensin I-converting enzyme inhibitor in elderly Japanese inpatients according to insertion/deletion polymorphism of the angiotensin I-converting enzyme gene.
Takahashi T; Morimoto S; Okaishi K; Kanda T; Nakahashi T; Okuro M; Murai H; Nishimura Y; Iwai K; Matsumoto M
Am J Hypertens; 2005 Oct; 18(10):1353-9. PubMed ID: 16202861
[TBL] [Abstract][Full Text] [Related]
3. PROGRESS - Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline. Progress Management Committee.
J Hypertens; 1999 Nov; 17(11):1647-55. PubMed ID: 10608480
[TBL] [Abstract][Full Text] [Related]
4. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
PROGRESS Collaborative Group
Lancet; 2001 Sep; 358(9287):1033-41. PubMed ID: 11589932
[TBL] [Abstract][Full Text] [Related]
5. Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial.
Fransen M; Anderson C; Chalmers J; Chapman N; Davis S; MacMahon S; Neal B; Sega R; Terent A; Tzourio C; Woodward M;
Stroke; 2003 Oct; 34(10):2333-8. PubMed ID: 12958329
[TBL] [Abstract][Full Text] [Related]
6. Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region.
Rodgers A; Chapman N; Woodward M; Liu LS; Colman S; Lee A; Chalmers J; MacMahon S;
J Hypertens; 2004 Mar; 22(3):653-9. PubMed ID: 15076173
[TBL] [Abstract][Full Text] [Related]
7. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack.
Arima H; Hart RG; Colman S; Chalmers J; Anderson C; Rodgers A; Woodward M; MacMahon S; Neal B;
Stroke; 2005 Oct; 36(10):2164-9. PubMed ID: 16141420
[TBL] [Abstract][Full Text] [Related]
8. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials.
Brugts JJ; Ninomiya T; Boersma E; Remme WJ; Bertrand M; Ferrari R; Fox K; MacMahon S; Chalmers J; Simoons ML
Eur Heart J; 2009 Jun; 30(11):1385-94. PubMed ID: 19346520
[TBL] [Abstract][Full Text] [Related]
9. ACE inhibitors and protection against pneumonia in elderly patients with stroke.
Arai T; Sekizawa K; Ohrui T; Fujiwara H; Yoshimi N; Matsuoka H; Sasaki H
Neurology; 2005 Feb; 64(3):573-4. PubMed ID: 15699404
[No Abstract] [Full Text] [Related]
10. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition.
Harrap SB; Tzourio C; Cambien F; Poirier O; Raoux S; Chalmers J; Chapman N; Colman S; Leguennec S; MacMahon S; Neal B; Ohkubo T; Woodward M;
Hypertension; 2003 Sep; 42(3):297-303. PubMed ID: 12925557
[TBL] [Abstract][Full Text] [Related]
11. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
Rapezzi C; Ciliberti P; Graziosi M; Riva L
Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
[TBL] [Abstract][Full Text] [Related]
12. Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS): interpretation and implementation.
Chalmers J; MacMahon S
J Hypertens Suppl; 2003 Jun; 21(5):S9-14. PubMed ID: 12953850
[TBL] [Abstract][Full Text] [Related]
13. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial.
Brugts JJ; Boersma E; Chonchol M; Deckers JW; Bertrand M; Remme WJ; Ferrari R; Fox K; Simoons ML;
J Am Coll Cardiol; 2007 Nov; 50(22):2148-55. PubMed ID: 18036453
[TBL] [Abstract][Full Text] [Related]
14. [Rationale, characteristics and study design of PREAMI (Perindopril and Remodelling in the Elderly with Acute Myocardial Infraction)].
Magrini G; Nicolosi GL; Chiariello M; Ferrari R; Remme P; Tavazzi L
Ital Heart J; 2005 Nov; 6 Suppl 7():14S-23S. PubMed ID: 16485513
[TBL] [Abstract][Full Text] [Related]
15. [Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI].
Ferrari R; Papa K; Bernocchi P; Gimbatti OJ; Golcea SS; Bettini A; Ceconi C
Ital Heart J; 2005 Nov; 6 Suppl 7():24S-32S. PubMed ID: 16485514
[TBL] [Abstract][Full Text] [Related]
16. PROGRESS (Perindopril Protection Against Recurrent Stroke Study): regional characteristics of the study population at baseline. PROGRESS Management Committee.
Chalmers J; Neal B; MacMahon S;
J Hypertens Suppl; 2000 May; 18(1):S13-9. PubMed ID: 10939785
[TBL] [Abstract][Full Text] [Related]
17. PROGRESS--perindopril protection against recurrent stroke study: status in July 1996. PROGRESS Management Committee.
J Hypertens Suppl; 1996 Dec; 14(6):S47-51. PubMed ID: 9023716
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients.
Liu CL; Shau WY; Wu CS; Lai MS
J Hypertens; 2012 Nov; 30(11):2223-9. PubMed ID: 22929610
[TBL] [Abstract][Full Text] [Related]
19. [PROGRESS--a trial on blood pressure lowering after stroke and TIA. ACE inhibitors and diuretics reduce the risk of new stroke].
Terént A
Lakartidningen; 2002 May; 99(20):2286-8, 2291. PubMed ID: 12082946
[No Abstract] [Full Text] [Related]
20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
